Shots:

• The EC’s approval is based on a P-III study assessing Dupixent (300mg- q4w & 200mg- q2w) + TCS vas TCS alone in children aged 6-11yrs. with severe AD
• Result: improvement in disease extent and severity (82% & 80% vs 49% & 48%); at least 75% improvement (70% & 75% vs 17% & 26%); skin clearance (33% & 39% vs 11% & 10%); reduction in itching (51% & 61% vs 12% & 13%); improvement in HR-QoL (77% & 81% vs 39% & 36%) respectively
• Dupixent is mAb that inhibits the signaling of IL-4 and IL-13 proteins and is the only systemic medicine approved in the EU to treat children with severe AD

 ­ Ref: Sanofi | Image: BioSpace